Provided by Tiger Fintech (Singapore) Pte. Ltd.

Ecopetrol SA

8.15
+0.09001.12%
Post-market: 8.150.00000.00%19:58 EDT
Volume:3.71M
Turnover:29.89M
Market Cap:16.76B
PE:4.95
High:8.21
Open:8.19
Low:7.95
Close:8.06
Loading ...

Ecopetrol (EC) Stock Falls Amid Market Uptick: What Investors Need to Know

Zacks
·
23 Apr

Central Bank warns Trump will bring crypto apocalypse in Europe

CoinMarketCap
·
22 Apr

Ecopetrol (EC) Declines More Than Market: Some Information for Investors

Zacks
·
16 Apr

Biogen reports EC grants marketing authorization for Leqembi

TIPRANKS
·
16 Apr

EC World REIT Director Resigns Amid Bankruptcy

TIPRANKS
·
14 Apr

Ecopetrol Signs Agreement to Develop 49% of Jemeiwaa Ka'I Wind Cluster in Colombia

MT Newswires Live
·
14 Apr

Ecopetrol, AES Colombia to build the Jemeiwaa Ka’I wind cluster in La Guajira

TIPRANKS
·
14 Apr

Ecopetrol Warns of Significant Hit to Profits Amid Lower Oil Price

Zacks
·
14 Apr

Press Release: Ecopetrol and AES Colombia sign an agreement to build the Jemeiwaa Ka'I wind cluster in La Guajira

Dow Jones
·
14 Apr

Are Oils-Energy Stocks Lagging Comstock Resources (CRK) This Year?

Zacks
·
14 Apr

Stocks to watch: Olam, EC World Reit, Hotel Properties Limited

businesstimes
·
14 Apr

TG Therapeutics Announces Data Presentations for BRIUMVI in Multiple Sclerosis at the American Academy of Neurology 2025 Annual Meeting

GlobeNewswire
·
10 Apr

European Commission Approved Subcutaneous DARZALEX® (daratumumab)-based Quadruplet Regimen for the Treatment of Patients with Newly Diagnosed Multiple Myeloma, Regardless of Transplant Eligibility

PR Newswire
·
09 Apr

VRTX Secures Nod for Expanded Use of CF Drug Kaftrio in Europe

Zacks
·
08 Apr

AbbVie Announces European Commission Approval of RINVOQ® (upadacitinib) for the Treatment of Adults with Giant Cell Arteritis

PR Newswire
·
08 Apr

J&J announces EC approved extension of marketing authorization for Rybrevant

TIPRANKS
·
08 Apr

Vertex Pharmaceuticals announces EC approval of expanded KAFTRIO label

TIPRANKS
·
08 Apr

European Commission Approves Subcutaneous RYBREVANT® (amivantamab) Co-Formulated with ENHANZE® for the Treatment of Patients with Advanced EGFR-Mutated Non-Small Cell Lung Cancer

PR Newswire
·
07 Apr

Corcept Initiates Trial of Relacorilant Plus Nab-Paclitaxel and Bevacizumab in Patients With Platinum-Resistant Ovarian Cancer

Business Wire
·
07 Apr

TG Therapeutics Announces Two Publications Highlighting BRIUMVI in Medical Journals

GlobeNewswire
·
07 Apr